AQP4 and neuromyelitis optica: Alternative NMO therapeutics under evaluation or development include monocloncal antibodies targeting IL-6 receptors on plasma cells (toculizumab, [37]) and NMO-IgG binding to AQP4 (aquaporumab, [38]), and small molecule inhibitors of neutrophils [39] and eosinophils [40].